Genomic Profiling for Prostate Cancer
Based on tumor biology alone, Decipher offers superior accuracy in predicting risk of progression, enabling the patient and physician to optimize clinical decisions.
Highest Reported Accuracy
independent of risk factors such as PSA, stage and Gleason score
unmatched by any other option available to physicians in the United States today
Standard of Care Testing
covered by Medicare and recommended by clinical practice guidelines
Decipher Prostate Biopsy is a genomic test performed on tumor tissue that helps match selection and intensity of treatment with the metastatic potential of the tumor.
Prostate cancer mortality
Clinical practice guidelines for prostate cancer
Sanjeev Kaul, MD
"For patients newly diagnosed with intermediate risk prostate cancer, Decipher is an invaluable tool to select between active surveillance and definitive therapy, and to guide intensity of radiation and ADT"
Physicians \ Order a Test
2. Fax the completed form, along with the pathology report and insurance information to:
Specimen Acceptance Criteria
ALL Gleason Scores
ALL PSA Values
ALL Gleason Scores
ALL PSA Values*
*Undetectable, rising, and persistently elevated PSA
of Bladder Tumor)
Urothelial/Transitional Cell Muscle Invasive Carcinoma
Patients \ Insurance Information
Decipher Biosciences is committed to ensuring access for all patients.
Decipher Prostate is covered by Medicare, Medicare Advantage and select private insurers.
Through Decipher Assist, we offer programs designed to ensure testing is affordable for patients, including:
• Financial assistance for patients with demonstrated financial need
• Tailored payment plans to accommodate certain specific financial circumstances
For more information on the Decipher test and Decipher Assist, please contact the Decipher Assist team at:
888.792.1601 or download the Decipher Assist brochure.
Decipher Bladder is available on a self-pay basis. For more information, please contact the Decipher team at: